Quantitative in vitro-to-in vivo extrapolation in a high-throughput environment

Toxicology

Volumn 332, Issue , 2015, Pages 94-101

  Wetmore, Barbara A ^a  

^a HAMNER INSTITUTES FOR HEALTH SCIENCES   (United States)

Author keywords

High throughput screening; Quantitative in vitro to in vivo extrapolation; Reverse dosimetry

Indexed keywords

2,4 DICHLOROPHENOXYACETIC ACID; 4,4' ISOPROPYLIDENEDIPHENOL; CACODYLIC ACID; CARBARIL; OXYTETRACYCLINE; PARATHION; PICLORAM; TIABENDAZOLE; TRICLOSAN; XENOBIOTIC AGENT;

ARTICLE; COMPARATIVE STUDY; DOSIMETRY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SCREENING; IN VITRO STUDY; LIVER CLEARANCE; MASS FRAGMENTOGRAPHY; METABOLIC CLEARANCE RATE; PRIORITY JOURNAL; PROTEIN BINDING; RISK ASSESSMENT; TOXICITY TESTING; ANIMAL; ANIMAL TESTING ALTERNATIVE; BIOLOGICAL MODEL; BIOTRANSFORMATION; COMPUTER SIMULATION; DOSE RESPONSE; HUMAN; LIVER CELL; METABOLISM; MONTE CARLO METHOD; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PROCEDURES; RISK FACTOR; TOXICOLOGY;

ADMINISTRATION, ORAL; ANIMAL TESTING ALTERNATIVES; ANIMALS; BIOTRANSFORMATION; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPATOCYTES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IN VITRO TECHNIQUES; MODELS, BIOLOGICAL; MONTE CARLO METHOD; PHARMACOKINETICS; RISK ASSESSMENT; RISK FACTORS; TOXICITY TESTS; TOXICOLOGY;

EID: 84930085761     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2014.05.012     Document Type: Article

References (62)

1. Andersen M.E., Clewell H.J., Tan Y.M., Butenhoff J.L., Olsen G.W. Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys - probing the determinants of long plasma half-lives. Toxicology 2006, 227:156-164.
2. Andersen M.E., Krewski D. Toxicity testing in the 21st century: bringing the vision to life. Toxicol. Sci. 2009, 107:324-330.
3. Austin R.P., Barton P., Mohmed S., Riley R.J. The binding of drugs to hepatocytes and its relationship to physicochemical properties. Drug Metab. Dispos. 2005, 33:419-425.
4. Barter Z.E., Bayliss M.K., Beaune P.H., Boobis A.R., Carlile D.J., Edwards R.J., Houston J.B., Lake B.G., Lipscomb J.C., Pelkonen O.R., Tucker G.T., Rostami-Hodjegan A. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein and hepatocellularity per gram of liver. Curr. Drug Metab. 2007, 8:33-45.
5. Basketter D.A., Clewell H., Kimber I., Rossi A., Blaauboer B., Burrier R., Daneshian M., Eskes C., Goldberg A., Hasiwa N., Hoffmann S., Jaworska J., Knudsen T.B., Landsiedel R., Leist M., Locke P., Maxwell G., McKim J., McVey E.A., Ouedraogo G., Patlewicz G., Pelkonen O., Roggen E., Rovida C., Ruhdel I., Schwarz M., Schepky A., Schoeters G., Skinner N., Trentz K., Turner M., Vanparys P., Yager J., Zurlo J., Hartung T. A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing - t4 report*. ALTEX 2012, 29:3-91.
6. Bhattacharya S., Zhang Q., Carmichael P.L., Boekelheide K., Andersen M.E. Toxicity testing in the 21st century: defining new risk assessment approaches based on perturbation of intracellular toxicity pathways. PLoS One 2011, 6:e20887. 10.1371/journal.pone.0020887.
7. Bjorklund H.V., Bylund G. Comparative pharmacokinetics and bioavailability of oxolinic acid and oxytetracycline in rainbow trout (Oncorhynchus mykiss). Xenobiotica 1991, 21:1511-1520.
8. Blaauboer B.J. Biokinetic modeling and in vitro-in vivo exptrapolations. J. Toxicol. Environ. Health Part B 2010, 13:242-252.
9. Boekelheide K., Andersen M.E. A mechanistic redefinition of adverse effects - a key step in the toxicity testing paradigm shift. ALTEX 2010, 27:243-252.
10. Chen Y., Jin J.Y., Mukadam S., Malhi V., Kenny J.R. Application of IVIVE and PBPK modeling in prospective prediction of clinical pharmacokinetics: strategy and approach during the drug discovery phase with four case studies. Biopharm. Drug Dispos. 2012.
11. Davies B., Morris T. Physiological parameters in laboratory animals and humans. Pharm. Res. 1993, 10:1093-1095.
12. De Buck S.S., Mackie C.E. Physiologically based approaches towards the prediction of pharmacokinetics: in vitro-in vivo extrapolation. Expert Opin. Drug Metab. Toxicol. 2007, 3:865-878.
13. Dix D.J., Houck K.A., Martin M.T., Richard A.M., Setzer R.W., Kavlock R.J. The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol. Sci. 2007, 95:5-12.
14. Gibson G.G., Rostami-Hodjegan A. Modelling and simulation in prediction of human xenobiotic absorption, distribution, metabolism and excretion (ADME): in vitro-in vivo extrapolations (IVIVE). Xenobiotica 2007, 37:1013-1014.
15. Hallifax D., Houston J.B. Uptake and intracellular binding of lipophilic amine drugs by isolated rat hepatocytes and implications for prediction of in vivo metabolic clearance. Drug Metab. Dispos. 2006, 34:1829-1836.
16. Hallifax D., Houston J.B. Saturable uptake of lipophilic amine drugs into isolated hepatocytes: mechanisms and consequences for quantitative clearance prediction. Drug Metab. Dispos. 2007, 35:1325-1332.
17. Houck K.A., Dix D.J., Judson R.S., Kavlock R.J., Yang J., Berg E.L. Profiling bioactivity of the ToxCast chemical library using BioMAP primary human cell systems. J. Biomol. Screen. 2009, 14:1054-1066.
18. Huang R., Xia M., Cho M.H., Sakamuru S., Shinn P., Houck K.A., Dix D.J., Judson R.S., Witt K.L., Kavlock R.J., Tice R.R., Austin C.P. Chemical genomics profiling of environmental chemical modulation of human nuclear receptors. Environ. Health Perspect. 2011, 119:1142-1148.
19. Jamei M., Marciniak S., Feng K., Barnett A., Tucker G., Rostami-Hodjegan A. The Simcyp((R)) population-based ADME Simulator. Expert Opin. Drug Metab. Toxicol. 2009.
20. Johnson T.N., Tucker G.T., Tanner M.S., Rostami-Hodjegan A. Changes in liver volume from birth to adulthood: a meta-analysis. Liver Transpl. 2005, 11:1481-1493.
21. Jones H.M., Houston J.B. Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab. Dispos. 2004, 32:973-982.
22. Judson R.S., Houck K.A., Kavlock R.J., Knudsen T.B., Martin M.T., Mortensen H.M., Reif D.M., Rotroff D.M., Shah I., Richard A.M., Dix D.J. In vitro screening of environmental chemicals for targeted testing prioritization: the ToxCast project. Environ. Health Perspect. 2010, 118:485-492.
23. Judson R.S., Kavlock R.J., Setzer R.W., Cohen Hubal E.A., Martin M.T., Knudsen T.B., Houck K.A., Thomas R.S., Wetmore B.A., Dix D.J. Estimating toxicity-related biological pathway altering doses for high-throughput chemical risk assessment. Chem. Res. Toxicol. 2011, 24:451-462.
24. Kavlock R.J., Austin C.P., Tice R.R. Toxicity testing in the 21st century: implications for human health risk assessment. Risk Anal. 2009, 29:485-487. discussion 492-487.
25. Keller D.A., Juberg D.R., Catlin N., Farland W.H., Hess F.G., Wolf D.C., Doerrer N.G. Identification and characterization of adverse effects in 21st century toxicology. Toxicol. Sci. 2012, 126:291-297.
26. Khan, M.T.H., 2009. Advances in ADMET predictions and modeling: rapid drug discovery efforts in 21st centuries. pp. 333-350.
27. Kilford P.J., Gertz M., Houston J.B., Galetin A. Hepatocellular binding of drugs: correction for unbound fraction in hepatocyte incubations using microsomal binding or drug lipophilicity data. Drug Metab. Dispos. 2008, 36:1194-1197.
28. Kleinstreuer N.C., Dix D.J., Houck K.A., Kavlock R.J., Knudsen T.B., Martin M.T., Paul K.B., Reif D.M., Crofton K.M., Hamilton K., Hunter R., Shah I., Judson R.S. In vitro perturbations of targets in cancer hallmark processes predict rodent chemical carcinogenesis. Toxicol. Sci. 2012, 131:40-55.
29. Kleinstreuer N.C., Judson R.S., Reif D.M., Sipes N.S., Singh A.V., Chandler K.J., Dewoskin R., Dix D.J., Kavlock R.J., Knudsen T.B. Environmental impact on vascular development predicted by high-throughput screening. Environ. Health Perspect. 2011, 119:1596-1603.
30. Kleinstreuer N.C., Judson R.S., Reif D.M., Sipes N.S., Singh A.V., Chandler K.J., Dewoskin R., Dix D.J., Kavlock R.J., Knudsen T.B. Environmental impact on vascular development predicted by high throughput screening. Environ. Health Perspect. 2011.
31. Knight A.W., Little S., Houck K., Dix D., Judson R., Richard A., McCarroll N., Akerman G., Yang C., Birrell L., Walmsley R.M. Evaluation of high-throughput genotoxicity assays used in profiling the US EPA ToxCast chemicals. Regul. Toxicol. Pharmacol. 2009, 55:188-199.
32. Knudsen T.B., Houck K.A., Sipes N.S., Singh A.V., Judson R.S., Martin M.T., Weissman A., Kleinstreuer N.C., Mortensen H.M., Reif D.M., Rabinowitz J.R., Setzer R.W., Richard A.M., Dix D.J., Kavlock R.J. Activity profiles of 309 ToxCast chemicals evaluated across 292 biochemical targets. Toxicology 2011, 282:1-15.
33. Lamb J., Crawford E.D., Peck D., Modell J.W., Blat I.C., Wrobel M.J., Lerner J., Brunet J.P., Subramanian A., Ross K.N., Reich M., Hieronymus H., Wei G., Armstrong S.A., Haggarty S.J., Clemons P.A., Wei R., Carr S.A., Lander E.S., Golub T.R. The connectivity map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935.
34. Li A.P., Lu C., Brent J.A., Pham C., Fackett A., Ruegg C.E., Silber P.M. Cryopreserved human hepatocytes: characterization of drug-metabolizing enzyme activities and applications in higher throughput screening assays for hepatotoxicity, metabolic stability, and drug-drug interaction potential. Chem. Biol. Interact. 1999, 121:17-35.
35. Li H., Qiu J., Fu X.D. RASL-seq for massively parallel and quantitative analysis of gene expression. Curr. Protoc. Mol. Biol. 2012, 13:11-19. Chapter 4, Unit 4.
36. Liao K.H., Tan Y.M., Clewell H.J. Development of a screening approach to interpret human biomonitoring data on volatile organic compounds: reverse dosimetry on biomonitoring data for trichloroethylene. Risk Anal. 2007, 27:1223-1236.
37. Loccisano A.E., Campbell J.L., Andersen M.E., Clewell H.J. Evaluation and prediction of pharmacokinetics of PFOA and PFOS in the monkey and human using a PBPK model. Regul. Toxicol. Pharmacol. 2010.
38. Martin M.T., Dix D.J., Judson R.S., Kavlock R.J., Reif D.M., Richard A.M., Rotroff D.M., Romanov S., Medvedev A., Poltoratskaya N., Gambarian M., Moeser M., Makarov S.S., Houck K.A. Impact of environmental chemicals on key transcription regulators and correlation to toxicity end points within EPA's ToxCast program. Chem. Res. Toxicol. 2010, 23:578-590.
39. Martin M.T., Knudsen T.B., Reif D.M., Houck K.A., Judson R.S., Kavlock R.J., Dix D.J. Predictive model of rat reproductive toxicity from ToxCast high throughput screening. Biol. Reprod. 2011, 85:327-339.
40. McGinnity D.F., Soars M.G., Urbanowicz R.A., Riley R.J. Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos. 2004, 32:1247-1253.
41. Naritomi Y., Terashita S., Kimura S., Suzuki A., Kagayama A., Sugiyama Y. Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos. 2001, 29:1316-1324.
42. Nielsen P., Gyrd-Hansen N. Bioavailability of oxytetracycline, tetracycline and chlortetracycline after oral administration to fed and fasted pigs. J. Vet. Pharmacol. Ther. 1996, 19:305-311.
43. NRC Toxicity Testing in the 21st Century: A Vision and a Strategy 2007, National Academy Press, Washington, D.C.
44. Obach R.S. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. 1999, 27:1350-1359.
45. Pelkonen O., Turpeinen M. In vitro-in vivo extrapolation of hepatic clearance: biological tools, scaling factors, model assumptions and correct concentrations. Xenobiotica 2007, 37:1066-1089.
46. Reif D.M., Martin M.T., Tan S.W., Houck K.A., Judson R.S., Richard A.M., Knudsen T.B., Dix D.J., Kavlock R.J. Endocrine profiling and prioritization of environmental chemicals using ToxCast data. Environ. Health Perspect. 2010, 118:1714-1720.
47. Rotroff D.M., Beam A.L., Dix D.J., Farmer A., Freeman K.M., Houck K.A., Judson R.S., LeCluyse E.L., Martin M.T., Reif D.M., Ferguson S.S. Xenobiotic-metabolizing enzyme and transporter gene expression in primary cultures of human hepatocytes modulated by ToxCast chemicals. J. Toxicol. Environ. Health B Crit. Rev. 2010, 13:329-346.
48. Rotroff D.M., Wetmore B.A., Dix D.J., Ferguson S.S., Clewell H.J., Houck K.A., Lecluyse E.L., Andersen M.E., Judson R.S., Smith C.M., Sochaski M.A., Kavlock R.J., Boellmann F., Martin M.T., Reif D.M., Wambaugh J.F., Thomas R.S. Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol. Sci. 2010, 117:348-358.
49. Rule A.D., Gussak H.M., Pond G.R., Bergstralh E.J., Stegall M.D., Cosio F.G., Larson T.S. Measured and estimated GFR in healthy potential kidney donors. Am. J. Kidney Dis. 2004, 43:112-119.
50. Shaffer C.L., Scialis R.J., Rong H., Obach R.S. Using Simcyp to project human oral pharmacokinetic variability in early drug research to mitigate mechanism-based adverse events. Biopharm. Drug Dispos. 2011.
51. Shah I., Houck K., Judson R.S., Kavlock R.J., Martin M.T., Reif D.M., Wambaugh J., Dix D.J. Using nuclear receptor activity to stratify hepatocarcinogens. PLoS One 2011, 6:e14584.
52. Shukla S.J., Huang R., Austin C.P., Xia M. The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform. Drug Discov. Today 2010, 15:997-1007.
53. Sipes N.S., Martin M.T., Reif D.M., Kleinstreuer N.C., Judson R.S., Singh A.V., Chandler K.J., Dix D.J., Kavlock R.J., Knudsen T.B. Predictive models of prenatal developmental toxicity from ToxCast high-throughput screening data. Toxicol. Sci. 2011, 124:109-127.
54. Takeuchi S., Matsuda T., Kobayashi S., Takahashi T., Kojima H. In vitro screening of 200 pesticides for agonistic activity via mouse peroxisome proliferator-activated receptor (PPAR)alpha and PPARgamma and quantitative analysis of in vivo induction pathway. Toxicol. Appl. Pharmacol. 2006, 217:235-244.
55. Thomas R.S., Black M.B., Li L., Healy E., Chu T.M., Bao W., Andersen M.E., Wolfinger R.D. A comprehensive statistical analysis of predicting in vivo hazard using high-throughput in vitro screening. Toxicol. Sci. 2012, 128:398-417.
56. Thomas R.S., Philbert M.A., Auerbach S.S., Wetmore B.A., Devito M.J., Cote I., Rowlands J.C., Whelan M.P., Hays S.M., Andersen M.E., Meek M.E., Reiter L.W., Lambert J.C., Clewell H.J., Stephens M.L., Zhao Q.J., Wesselkamper S.C., Flowers L., Carney E.W., Pastoor T.P., Petersen D.D., Yauk C.L., Nong A. Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol. Sci. 2013, 136:4-18.
57. Tonnelier A., Coecke S., Zaldivar J.M. Screening of chemicals for human bioaccumulative potential with a physiologically based toxicokinetic model. Arch. Toxicol. 2012, 86:393-403.
58. Völkel W., Colnot T., Csanády G.A., Filser J.G., Dekant W. Metabolism and kinetics of bisphenol a in humans at low doses following oral administration. Chem. Res. Toxicol. 2002, 15:1281-1287.
59. Waters N.J., Jones R., Williams G., Sohal B. Validation of a rapid equilibrium dialysis approach for the measurement of plasma protein binding. J. Pharm. Sci. 2008, 97:4586-4595.
60. Wetmore B.A., Wambaugh J.F., Ferguson S.S., Li L., Clewell H.J., Judson R.S., Freeman K., Bao W., Sochaski M.A., Chu T.M., Black M.B., Healy E., Allen B., Andersen M.E., Wolfinger R.D., Thomas R.S. Relative impact of incorporating pharmacokinetics on predicting in vivo hazard and mode of action from high-throughput in vitro toxicity assays. Toxicol. Sci. 2013, 132:327-346.
61. Wetmore B.A., Wambaugh J.F., Ferguson S.S., Sochaski M.A., Rotroff D.M., Freeman K., Clewell H.J., Dix D.J., Andersen M.E., Houck K.A., Allen B., Judson R.S., Singh R., Kavlock R.J., Richard A.M., Thomas R.S. Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol. Sci. 2012, 125:157-174.
62. Wilkinson R.G., Shand D.G. A physiological approach to hepatic drug clearance. Clin. Pharmacol. Ther. 1975, 18:377-389.